GnRH antagonist is named as a drug or biological intervention in 4 clinical trials in our China and USA trial registers, 3 of which are recruiting. Lead sponsors include Xiaojun Chen (2), Amgen (1) and ShangHai Ji Ai Genetics & IVF Institute (1). Registered phases: Phase 2/3, Phase 1 and Phase 3. Conditions studied include Atypical Endometrial Hyperplasia; Progesterone Resistance; Obesity.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05447208 | Effect of GH on the Blastocyst Euploid Rate in AMA Patients (ClinicalTrials.gov ↗) Preimplantation Genetic Testing, Growth Hormone, Age, Parental |
Phase 3 | Recruiting |
| NCT06379113 | GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients (ClinicalTrials.gov ↗) Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance |
Phase 2/3 | Recruiting |
| NCT06613100 | Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer Prostate Cancer |
Phase 1 | Recruiting |
| NCT06390904 | GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients (ClinicalTrials.gov ↗) Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity |
Phase 2/3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Atypical Endometrial Hyperplasia | 2 |
| Progesterone Resistance | 2 |
| Obesity | 2 |
| Prostate Cancer | 1 |
| Preimplantation Genetic Testing | 1 |
| Growth Hormone | 1 |
| Age, Parental | 1 |
| Endometrial Neoplasms | 1 |
| Lead sponsor | Trials |
|---|---|
| Xiaojun Chen | 2 |
| Amgen | 1 |
| ShangHai Ji Ai Genetics & IVF Institute | 1 |
| Register | GnRH antagonist trials |
|---|---|
| Clinical trials in China | 3 |
| Clinical trials in USA | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how GnRH antagonist works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GnRH antagonist (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.